CHK112 Oct 2022 14:07
I think this is simply a case of Competition Management and an authorities instruction?
It is entirely possible that GSK already have their version of SRA737 in the pipeline and were therefore restricted from keeping SRA737 in their portfolio as well, thus having no choice but to hand it back to Sareum...Of course this is speculation, but makes more sense to me.